Russell Investments Group
INMB icon

Russell Investments Group’s INmune Bio INMB Stock Holding History

Russell Investments Group’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.8K Buy
13,993
+11,434
+447% +$16.3K ﹤0.01% 3680
2025
Q4 		$3.99K Sell
2,559
-9,171
-78% -$16.4K ﹤0.01% 3934
2025
Q3 		$24.3K Buy
+11,730
New +$26.9K ﹤0.01% 3539

Other funds holding INMB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Russell Investments Group's INMB Position: Q1 2026 in Review

Russell Investments Group increased its INmune Bio (INMB) stake by 447% in Q1 2026, buying an estimated $16.3K and bringing the position to 13,993 shares worth $15.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3680.

Russell Investments Group first reported a position in INMB in Q3 2025 and has held it in 3 quarters since. The position peaked at $24.3K in Q3 2025. 82 funds tracked by Wall St. Rank hold INMB as of Q1 2026.

  • Russell Investments Group held 13,993 shares of INmune Bio worth $15.8K as of Q1 2026.
  • Russell Investments Group bought 11,434 INmune Bio shares in Q1 2026, an estimated $16.3K.
  • INmune Bio made up ﹤0.01% of Russell Investments Group's portfolio in Q1 2026, its #3680 holding.
  • Russell Investments Group first reported a position in INmune Bio in Q3 2025 and has held it in 3 quarters since.
  • Russell Investments Group's INmune Bio position peaked at $24.3K in Q3 2025.
  • 82 funds tracked by Wall St. Rank held INmune Bio as of Q1 2026.

Based on Russell Investments Group's 13F filing for Q1 2026, filed 8 May 2026.